Preprint describes DNA methylation signature to identify individuals at epigenetic risk for FSHD
The D4Z4caster assay uses targeted bisulfite sequencing of the D4Z4 repeat array to stratify individuals who may carry the epigenetic hallmarks of facioscapulohumeral muscular dystrophy.
A preprint posted to bioRxiv introduces D4Z4caster, a targeted DNA methylation assay designed to characterise the epigenetic state of the D4Z4 repeat array on chromosome 4q35 — the genomic region whose hypomethylation underlies facioscapulohumeral muscular dystrophy (FSHD).
FSHD is caused by epigenetic derepression of the DUX4 gene within the D4Z4 array, which occurs under specific permissive genetic conditions. Conventional genetic confirmation is technically demanding, costly, and not widely accessible, meaning that many individuals with characteristic proximal muscle weakness — and at-risk relatives — remain without a molecular diagnosis.
The authors report that D4Z4caster uses bisulfite sequencing at specific D4Z4 loci to distinguish the two main genetic forms of FSHD (FSHD1 and FSHD2) from one another and from unaffected individuals. The method is presented as potentially more accessible than current gold-standard approaches.
Genetic counsellors and neuromuscular disease researchers will note that the assay is described as a research tool; the authors do not present it as a validated clinical diagnostic. The preprint has not yet been peer-reviewed, and independent validation in diverse populations would be required before any research or educational conclusions could be drawn about its broader applicability.
This study is a preprint and has not yet been peer-reviewed.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited muscle condition that causes weakness, particularly in the face, shoulders and upper arms. It is caused by changes in how a part of chromosome 4 is chemically marked — a process called DNA methylation — rather than a simple spelling change in the genetic code.
Researchers have described a new laboratory test, called D4Z4caster, that reads these chemical marks on the relevant chromosome region. In the preprint paper, it correctly distinguished people with FSHD from those without, and told apart two different genetic forms of the condition. The scientists suggest it could be easier to perform than current tests, which are complex and not always available.
This research is at an early stage and has not yet been checked by independent scientific reviewers. It is a research tool, not a diagnostic test available in clinics.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-29The D4Z4caster DNA methylation signature identifies individuals at epigenetic risk for developing facioscapulohumeral muscular dystrophy (FSHD)